About Centogene ag
Centogene AG: Revolutionizing Genetic Diagnostics for Rare Diseases
Centogene AG is a global leader in the field of genetic diagnostics for rare diseases. The company is dedicated to improving patients' lives every day by providing accurate and reliable genetic testing services. With its state-of-the-art technology and expertise, Centogene has become a trusted partner for healthcare providers, researchers, and patients worldwide.
Founded in 2006, Centogene has grown rapidly over the years and now operates in more than 130 countries. The company's headquarters are located in Rostock, Germany, with additional offices in Berlin, Vienna, Dubai, Boston, and Mumbai. Centogene employs over 600 people from diverse backgrounds who share a common goal of making a difference in the lives of patients with rare diseases.
What sets Centogene apart from other genetic testing companies is its focus on rare diseases. These are conditions that affect fewer than one person per 2,000 individuals. There are over 7,000 known rare diseases worldwide that collectively affect millions of people globally. However, due to their rarity and complexity, many of these conditions remain undiagnosed or misdiagnosed for years.
This is where Centogene comes into play - by offering comprehensive genetic testing services that can help diagnose even the most challenging cases. The company's portfolio includes whole exome sequencing (WES), whole genome sequencing (WGS), targeted gene panels (TGP), RNA sequencing (RNAseq), epigenetic analysis (MethylSeq), as well as bioinformatics analysis tools.
Centogene's diagnostic approach combines cutting-edge technology with clinical expertise to provide personalized solutions tailored to each patient's needs. The company works closely with healthcare providers to ensure that patients receive timely and accurate diagnoses that can guide their treatment decisions.
In addition to diagnostic services, Centogene also offers research solutions aimed at advancing our understanding of rare diseases. Through collaborations with academic institutions and pharmaceutical companies worldwide,
Centogene has contributed significantly to the development of new therapies for various rare conditions such as spinal muscular atrophy (SMA) or cystic fibrosis (CF).
One example is CENTOGENE’s involvement in Project HERCULES – an international consortium focused on developing treatments for Friedreich’s Ataxia – a debilitating neurodegenerative disease affecting approximately one out of every 50k-100k individuals globally.
Another example is CENTOGENE’s partnership with Orphazyme A/S – a Danish biopharmaceutical company focused on developing therapies for lysosomal storage disorders such as Niemann-Pick disease type C1(NPC1). Together they aim at identifying novel biomarkers which could be used both clinically but also serve as endpoints during clinical trials evaluating potential treatments against NPC1 disease
Overall,Centogenes’ mission goes beyond just providing diagnostic services; it aims at improving patient outcomes through innovative research initiatives aimed at finding cures or better treatments options against some devastating orphan disorders.
In conclusion,Centogenes’ commitment towards revolutionizing genetic diagnostics through cutting-edge technologies combined with clinical expertise makes it an industry leader when it comes down diagnosing complex cases related to orphan disorders.Centogenes’ contribution towards advancing scientific knowledge about these conditions will undoubtedly lead us closer towards finding cures or better treatment options against some devastating orphan disorders which have been neglected so far due their rarity .